[Assay of plasma thrombomodulin in systemic diseases]

Rev Med Interne. 1997;18(2):126-31. doi: 10.1016/s0248-8663(97)84678-4.
[Article in French]

Abstract

Membrane thrombomodulin (TM) is a very efficient natural anti-thrombin glycoprotein with anticoagulant properties expressed on endothelial cell surface. Circulating plasmatic thrombomodulin (TMp) detected by enzyme immunoassay in plasma is considered as a cell marker of endothelial injury. The TMp levels are increased in many conditions (diabetes mellitus, atheromatous disease...). In cases of collagen vascular diseases, where vascular endothelium damage is suspected, TMp is increased particularly in systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). It is noteworthy that the TMp level is correlated with disease activity. Since TMp is a non specific marker of endothelial damage, it may be of interest as a useful marker for the supervision of these diseases. Further studies are needed on larger series. TMp level change during spontaneous evolution or under treatment will help determine wether TMp is a predictor and prognostic marker of these systemic diseases.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Acute Disease
  • Connective Tissue Diseases / blood*
  • Dermatomyositis / blood
  • Humans
  • Lupus Erythematosus, Systemic / blood
  • Scleroderma, Systemic / blood
  • Thrombomodulin / blood*

Substances

  • Thrombomodulin